Olzapin (Olanzapine)

Olanzapine, the active component of Olzapin, is used in the treatment of major psychiatric disorders that involve dopamine and serotonin dysregulation.

• Schizophrenia: reduces psychotic symptoms such as delusions, hallucinations, and thought disorder, helping to maintain stability.
• Bipolar disorder: controls manic episodes and stabilizes mood, decreasing the frequency of mood swings.
• Acute psychotic episodes: provides rapid symptom relief when used as part of an acute treatment regimen.

• Olanzapine acts primarily as an antagonist at dopamine D2 and serotonin 5‑HT2A receptors, while also influencing other neurotransmitter systems such as histamine H1, muscarinic, and adrenergic receptors. This receptor profile reduces dopaminergic over‑activity and modulates serotonergic pathways, leading to antipsychotic and mood‑stabilising effects.

Olzapin may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Weight gain: increase in body weight and appetite.
• Sedation: drowsiness or feeling unusually sleepy.
• Dry mouth: reduced salivation leading to discomfort.
• Constipation: slowed bowel movements.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: potentially life‑threatening reaction with fever, muscle rigidity, and autonomic instability.
• Agranulocytosis: severe reduction in white blood cells increasing infection risk.
• Tardive dyskinesia: persistent involuntary movements, often of the face and tongue.

When prescribing Olzapin, clinicians should observe several safety considerations to minimize risk.

• Metabolic monitoring: regularly assess weight, blood glucose, and lipid profile.
• Cardiovascular assessment: evaluate for pre‑existing heart disease and monitor blood pressure.
• Seizure risk: use cautiously in patients with a history of seizures.
• Elderly use: avoid in patients with dementia‑related psychosis due to increased mortality.
• Discontinuation: do not stop abruptly; taper under medical supervision.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olzapin can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Strong CYP1A2 inhibitors (e.g., fluvoxamine): can markedly increase olanzapine plasma levels.
• Other dopamine antagonists: additive central nervous system depression and extrapyramidal symptoms.
• QT‑prolonging agents: may increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce olanzapine concentrations, decreasing efficacy.
• Antihypertensive drugs: olanzapine can enhance hypotensive effects, requiring blood pressure monitoring.